As of June 3, 2025, ContraFect Corp (CFRX) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing ContraFect Corp's Gross Margin to Peers
To better understand ContraFect Corp's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| ContraFect Corp (CFRX) | 7775.20% |
| Galectin Therapeutics Inc (GALT) | 7775.20% |
| Eledon Pharmaceuticals Inc (ELDN) | 7775.20% |
| Alpine Immune Sciences Inc (ALPN) | 7775.20% |
| Capricor Therapeutics Inc (CAPR) | 7775.20% |
| Sio Gene Therapies Inc (SIOX) | 7775.20% |
Compared to its competitors, ContraFect Corp's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.